New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.

abstract：:Carvedilol is a beta-blocker with ancillary properties. Pilot clinical studies with carvedilol, added to the standard therapy of digoxin, diuretics and ACE inhibitors, showed beneficial effects in mild, moderate and severe heart failure. Patients consistently showed improvement in LV ejection fraction and NYHA functio...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2001-05-01 00:00:00

abstract：INTRODUCTION:Thermo transient receptor potential (thermoTRP) channels are some of the most intensely pursued therapeutic targets of the past decade. They are considered promising targets of numerous diseases including chronic pain and cancer. Modulators of these proteins, in particular TRPV1-4, TRPM8 and TRPA1, have re...

journal_title：Expert opinion on investigational drugs

authors： Fernández-Carvajal A,González-Muñiz R,Fernández-Ballester G,Ferrer-Montiel A

更新日期：2020-11-01 00:00:00

abstract：INTRODUCTION:Currently, there is no cure available for the hereditary neurodegenerative disease proximal spinal muscular atrophy (SMA), which is the number one genetic killer in early childhood. However, growing knowledge of SMA pathophysiology has opened new avenues for potential therapeutic interventions. AREAS COVE...

journal_title：Expert opinion on investigational drugs

authors： Kaczmarek A,Schneider S,Wirth B,Riessland M

更新日期：2015-01-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Migraine is an episodic, substantially inherited brain disorder affecting 15% of adults in Western Europe and North America, and is one of the commonest reasons for patients to see their physicians. While the World Health Organization considers that severe migraine can be as disabling as quadrip...

journal_title：Expert opinion on investigational drugs

authors： Marin JC,Goadsby PJ

更新日期：2010-04-01 00:00:00

abstract：:CGRP is a potent vasodilator that has been shown to have a physiological and/or pathological role in neurogenic inflammation, headaches including migraine, thermal injury, circulatory shock, pregnancy and menopause, hypertension and heart failure and is known to be cardioprotective. CGRP is also a positive inotrope an...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2001-06-01 00:00:00

abstract：:Proliferative diabetic retinopathy (PDR) demands both more effective and less expensive biologically based treatments. Our understanding of the pathophysiology of the disease is increasing as new biochemical pathways are identified. Most reports emphasize proangiogenic stimuli, with the natural inhibitory elements rec...

journal_title：Expert opinion on investigational drugs

authors： Hernández C,Simó R

更新日期：2007-08-01 00:00:00

abstract：:Introduction: The conventional management of most patients with metastatic urothelial carcinoma (UC) is platinum-based chemotherapy followed by immunotherapy. Erdafitinib is an option in post-platinum patients with activating mutations in fibroblast growth factor receptor (FGFR)-3 and -2. Salvage therapy with taxanes ...

journal_title：Expert opinion on investigational drugs

authors： McGregor BA,Sonpavde G

更新日期：2019-10-01 00:00:00

abstract：:Binding of microbial cell surface adhesins to host receptor molecules is a critical early step in microbial infection and pathogenesis. Anti-adhesive strategies aimed at blocking this interaction offer an attractive means of preventing infection at an early stage. The strategy should reduce the likelihood of resistant...

journal_title：Expert opinion on investigational drugs

authors： Kelly CG,Younson JS

更新日期：2000-08-01 00:00:00

abstract：INTRODUCTION:Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targete...

journal_title：Expert opinion on investigational drugs

authors： Vangapandu HV,Jain N,Gandhi V

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. and pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. OBJECTIVE:This drug evaluation foc...

journal_title：Expert opinion on investigational drugs

authors： Poulakou G,Giamarellou H

更新日期：2008-05-01 00:00:00

abstract：INTRODUCTION:Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over standard platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients. The development of acquired resistance to crizotinib represents an ongoing...

journal_title：Expert opinion on investigational drugs

authors： Karachaliou N,Santarpia M,Gonzalez Cao M,Teixido C,Sosa AE,Berenguer J,Rodriguez Capote A,Altavilla G,Rosell R

更新日期：2017-06-01 00:00:00

abstract：:IL-5 is the predominant cytokine associated with antigen-induced eosinophilic inflammation in the lung. The activation of Th-2 cells leads to the production of IL-5. The pro-eosinophilic effects of IL-5 include: (1) enhanced replication and differentiation of eosinophilic myelocytes; (2) enhanced degranulation of eosi...

journal_title：Expert opinion on investigational drugs

authors： Weltman JK,Karim AS

更新日期：2000-03-01 00:00:00

abstract：INTRODUCTION:Due to improvements in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), several target drugs have been and are being developed. One of the possible targets in SLE is co-stimulation between antigen-presenting cells and T cells. Abatacept is a co-stimulation moderator approved for...

journal_title：Expert opinion on investigational drugs

authors： Pimentel-Quiroz VR,Ugarte-Gil MF,Alarcón GS

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal...

journal_title：Expert opinion on investigational drugs

authors： Elicin O,Ozsahin M

更新日期：2016-06-01 00:00:00

abstract：:Hepatitis C virus is the most common chronic, blood-bourne infection, affecting 170 million people worldwide, approximately 3% of the global population. Of those infected with hepatitis C virus, 50 - 85% will develop chronic hepatitis C. Although hepatitis C is primarily a disease of the liver, a diagnosis is currentl...

journal_title：Expert opinion on investigational drugs

authors： Pockros PJ

更新日期：2002-04-01 00:00:00

abstract：INTRODUCTION:The current standard treatment in persons with hemophilia (PWH) is prophylaxis, given intravenously twice or thrice weekly, which is associated with a non negligible burden on patients' quality of life. Therefore the main attempts aiming to improve the management of PWH are targeted towards the development...

journal_title：Expert opinion on investigational drugs

authors： Mannucci PM,Mancuso ME

更新日期：2013-08-01 00:00:00

abstract：:Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticoster...

journal_title：Expert opinion on investigational drugs

authors： Fam AG

更新日期：2001-07-01 00:00:00

abstract：BACKGROUND:Peritoneal carcinomatosis (PC) is a challenging consequence of certain malignancies, associated with a poor prognosis and limited treatment options. Generally, PC has been treated similarly to metastatic cancers of the primary tumor, but associated with worse outcomes when compared to other sites of metastat...

journal_title：Expert opinion on investigational drugs

authors： Davies JM,O'Neil B

更新日期：2009-07-01 00:00:00

abstract：INTRODUCTION:The introduction and exploration of novel agents has significantly improved patient outcome in the treatment of multiple myeloma (MM). One such compound, bortezomib, was the first proteasome inhibitor (PI) to be approved as a MM therapeutic. The efficacy and safety data provided by bortezomib usage has pro...

journal_title：Expert opinion on investigational drugs

authors： Bringhen S,Gay F,Donato F,Troia R,Mina R,Palumbo A

更新日期：2014-09-01 00:00:00

abstract：INTRODUCTION:Posttraumatic stress disorder (PTSD) is a prevalent, chronic and disabling anxiety disorder that may develop following exposure to a traumatic event. There is currently no effective pharmacotherapy for PTSD and therefore the discovery of novel, evidence-based treatments is particularly important. This revi...

journal_title：Expert opinion on investigational drugs

authors： Ragen BJ,Seidel J,Chollak C,Pietrzak RH,Neumeister A

更新日期：2015-05-01 00:00:00

abstract：INTRODUCTION:EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreatic cancer. Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment. AREAS COVERED:This article focuses on the different generations of EGFR tyrosi...

journal_title：Expert opinion on investigational drugs

authors： Lee CC,Shiao HY,Wang WC,Hsieh HP

更新日期：2014-10-01 00:00:00

abstract：:Immunosuppressant drugs are crucial in order to protect transplanted kidney, heart or liver against the body's natural defence mechanisms. These drugs are used to prevent both acute rejection of the organ as well as chronic deterioration of the graft over longer periods of time. Currently used immunosuppressant drugs ...

journal_title：Expert opinion on investigational drugs

authors： Jorga A,Johnston A

更新日期：2005-03-01 00:00:00

abstract：:Obesity shortens life expectancy and is a risk factor for hypertension and Type 2 diabetes. When added to the standard chow of Sprague-Dawley or Otsuka Long-Evans Tokushima Fatty rats, alpha-lipoic acid (0.5% weight/weight) reduced body weight and food intake. Alpha-lipoic acid also increased whole-body energy expendi...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2004-12-01 00:00:00

abstract：:The topics discussed at this conference covered many aspects of the pathogenesis, epidemiology, diagnosis and treatment of rheumatic diseases, from the search of new therapeutic targets and evaluation of new diagnostic techniques to preclinical and clinical development of novel therapies. This contribution focuses pri...

journal_title：Expert opinion on investigational drugs

authors： Hellmich B,Gross WL

更新日期：2003-10-01 00:00:00

abstract：INTRODUCTION:Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Le...

journal_title：Expert opinion on investigational drugs

authors： Garciaz S,Coso D,Schiano de Colella JM,Bouabdallah R

更新日期：2016-09-01 00:00:00

abstract：:The introduction of HIV-1 protease inhibitors in 1995 ushered in the era of highly active antiretroviral therapy. For the first time, inhibition of two key enzymes responsible for HIV replication, reverse transcriptase and protease, was possible. The combination of two nucleoside reverse transcriptase inhibitors with ...

journal_title：Expert opinion on investigational drugs

authors： Piliero PJ

更新日期：2002-09-01 00:00:00

abstract：INTRODUCTION:Dyslipidemia is one of the most important risk factors for cardiovascular disease. Insufficient reduction in LDL-C from existing therapies in patients at high risk of atherogenic cardiovascular disease is an unmet clinical need. Circulating PCSK9 causes hypercholesterolemia by reducing LDL receptors in hep...

journal_title：Expert opinion on investigational drugs

authors： Nishikido T,Ray KK

更新日期：2018-03-01 00:00:00

abstract：:Gene transfer technology is under exploration to find therapies for the treatment of Parkinson's disease (PD) and other neurodegenerative disorders. The technology of genetic transfer can also be used as a neurobiological tool to understand the role of various genes in animal models of neurodegeneration. We describe t...

journal_title：Expert opinion on investigational drugs

authors： Frim DM,Kang UJ

更新日期：1999-10-01 00:00:00

abstract：:Restenosis, the re-narrowing of the lumen of the coronary artery, in the months following a successful percutaneous balloon angioplasty or stenting, remains the main limitation to percutaneous coronary revascularisation. Serial intravascular ultrasound studies have shown that restenosis after conventional balloon angi...

journal_title：Expert opinion on investigational drugs

authors： Gruberg L,Waksman R,Satler LF,Pichard AD,Kent KM

更新日期：2000-11-01 00:00:00

abstract：INTRODUCTION:Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of...

journal_title：Expert opinion on investigational drugs

authors： Smith-Harrison L,Starke NR,Smith RP,Kovac JR

更新日期：2017-06-01 00:00:00